Menu Search
Equities

Takeda Pharmaceutical Co Ltd

4502:TYO

Takeda Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)4,113.00
  • Today's Change-8.00 / -0.19%
  • Shares traded2.66m
  • 1 Year change-1.72%
  • Beta0.9146
Data delayed at least 20 minutes, as of Nov 22 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
OPERATIONS
Net income144,197317,038230,166
Depreciation/depletion728,002664,400583,151
Non-Cash items182,842327,626252,109
Cash taxes paid, supplemental202,039185,966140,423
Cash interest paid, supplemental100,375108,555108,207
Changes in working capital(338697)(331908)57,679
Total cash from operations716,344977,1561,123,105
INVESTING
Capital expenditures(480730)(633689)(186037)
Other investing and cash flow items, total16,86826,587(12088)
Total cash from investing(463862)(607102)(198125)
FINANCING
Financing cash flow items(126478)(117732)(108592)
Total cash dividends paid(287188)(279416)(283665)
Issuance (retirement) of stock, net(2326)(26929)(77531)
Issuance (retirement) of debt, net61,576(285071)(600477)
Total cash from financing(354416)(709148)(1070265)
NET CHANGE IN CASH
Foreign exchange effects26,20422,92928,758
Net change in cash(75730)(316165)(116527)
Net cash-begin balance/reserved for future use533,530849,695966,222
Net cash-end balance/reserved for future use457,800533,530849,695
SUPPLEMENTAL INCOME
Depreciation, supplemental728,002664,400583,151
Cash interest paid, supplemental100,375108,555108,207
Cash taxes paid, supplemental202,039185,966140,423
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.